December 16, 2019
 

DSM launches its latest breakthrough innovation Balancius in Thailand

 

 

  

DSM announces that Balancius™, the latest innovation developed within its Alliance with Novozymes, is now available in Thailand.

 

Balancius™ is a microbial muramidase designed to support gastrointestinal functionality thereof optimizing the feed efficiency and consequently supporting the sustainability of broiler production. Successfully launched in the USA and Latin America in September 2018, Balancius™ is also authorized for sale for broilers in all EU countries (Regulation (EU) 2019/805 of 17/05/2019), as well as in South Africa, Nigeria, Serbia & South Asia.

 

An innovative feed ingredient, Balancius™ hydrolyses the major cell wall component (peptidoglycan) in the dead bacteria, present in the gut, thus improving nutrients availability. This unique mode of action differentiates it from the other solutions in this space, which target indirectly living bacteria. By including Balancius™ in the feed for broilers, feed producers can improve feed conversion ratio by 4–6 points (3%), translating to significant cost savings. Balancius™ has also been shown to substantially increase breast meat yield and to enhance animal welfare through drier litter.

 

"Today marks a new milestone in the Balancius™ expansion story," said Pieter Nuboer, Vice President Animal Nutrition & Health APAC, DSM. "As the number of people on this earth rises, so does the global demand for the production of sustainable food and it is our responsibility to develop innovative solutions that will meet the challenges we face now and in the future. More than half of the world's population lives in Asia, and the launch of Balancius™ in this region will have a powerful impact on improving feed utilization and driving more sustainable food systems."

           

Balancius™ is the latest innovation from the Alliance of DSM with Novozymes, reflecting the strength of its scientific capabilities as well as its capacity to significantly and responsibly improve sustainable animal production.

 

"Together DSM and Novozymes have developed a solution that contributes to the growth and welfare of animals by digesting bacterial cell debris from the gut. No other technology works like this" says Susanne PalstenBuchardt, Vice President Commercial at Novozymes for Animal Health & Nutrition. "It's a game-changing innovation based on our 20 years Alliance with DSM."

 

"As a leader in Animal Nutrition & Health, we are at the forefront of innovation and sustainability. The launch of Balancius™ is a testimony of our leadership position, which we will further expand with our world-class research and development capabilities and with the broadest species-specific solution offer in the industry", explains Sebastian Marten, Vice President Enzymes &Eubiotics, Animal Nutrition & Health, DSM.

 

Based on the FAO's estimates of greenhouse gas emissions in chicken production, Balancius™ could reduce C02 emissions by an estimated 9 Mio tons globally - the equivalent of 3.7 million cars being taken off the road*.

 

Today's announcement is supported by data from more than 80 international research and customer evaluation studies.

 

In addition to Thailand, Balancius™ is available in South Asia, in the EU, in most Latin American countries, and the USA.

 

More information can be found at www.dsm.com.